ARMP
Income statement / Annual
Last year (2023), Armata Pharmaceuticals, Inc.'s total revenue was $4.53 M,
a decrease of 17.77% from the previous year.
In 2023, Armata Pharmaceuticals, Inc.'s net income was -$69.05 M.
See Armata Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$4.53 M
|
$5.51 M
|
$4.47 M
|
$823,000.00
|
$0.00
|
$0.00
|
$115,000.00
|
$260,000.00
|
$475,000.00
|
$409,000.00
|
| Cost of Revenue |
$33.77 M |
$892,000.00 |
$20.02 M |
$14.44 M |
$1.35 M |
$1.35 M |
$374,000.00 |
$369,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$29.24 M |
$4.62 M |
-$15.54 M |
-$13.62 M |
-$1.35 M |
-$1.35 M |
-$259,000.00 |
-$109,000.00 |
$475,000.00 |
$409,000.00 |
| Gross Profit Ratio |
-6.46 |
0.84 |
-3.47 |
-16.55 |
0 |
0 |
-2.25 |
-0.42 |
1 |
1 |
| Research and Development
Expenses |
$33.77 M
|
$35.02 M
|
$20.02 M
|
$14.44 M
|
$9.82 M
|
$4.89 M
|
$2.88 M
|
$5.68 M
|
$3.99 M
|
$5.81 M
|
| General & Administrative
Expenses |
$11.65 M
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$9.27 M
|
$5.70 M
|
$7.59 M
|
$8.41 M
|
$6.42 M
|
$6.85 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$289,000.00
|
$1.86 M
|
| Selling, General &
Administrative Expenses |
$11.65 M
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$9.27 M
|
$5.70 M
|
$7.59 M
|
$8.41 M
|
$6.71 M
|
$8.71 M
|
| Other Expenses |
-$33.77 M |
-$5.51 M |
-$4.47 M |
-$823,000.00 |
-$844,000.00 |
$1.93 M |
$6,000.00 |
-$554,000.00 |
-$302,000.00 |
$1.86 M |
| Operating Expenses |
$11.65 M |
$36.95 M |
$23.82 M |
$21.59 M |
$19.09 M |
$10.59 M |
$10.47 M |
$14.09 M |
$10.70 M |
$14.52 M |
| Cost And Expenses |
$45.42 M |
$36.95 M |
$23.82 M |
$21.59 M |
$19.09 M |
$10.59 M |
$10.47 M |
$14.09 M |
$10.70 M |
$14.52 M |
| Interest Income |
$179,000.00 |
$29,000.00 |
$5,000.00 |
$28,000.00 |
$96,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$2.63 M |
$29,000.00 |
$64,000.00 |
$628,000.00 |
$931,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$972,000.00
|
$892,000.00
|
$1.17 M
|
$1.11 M
|
$1.35 M
|
$1.35 M
|
$374,000.00
|
$369,000.00
|
$330,000.00
|
$158,000.00
|
| EBITDA |
-$39.92 M
|
-$36.05 M
|
-$22.65 M
|
-$20.44 M
|
-$19.75 M
|
-$9.54 M
|
-$9.98 M
|
-$13.46 M
|
-$10.23 M
|
-$14.11 M
|
| EBITDA Ratio |
-8.81 |
-6.55 |
-5.06 |
-24.83 |
0 |
0 |
-53.9 |
-32.51 |
-41.13 |
-125.11 |
| Operating Income Ratio
|
-9.03
|
-6.71
|
-5.32
|
-26.23
|
0
|
0
|
-140.49
|
-89.92
|
-21.53
|
-34.5
|
| Total Other
Income/Expenses Net |
-$28.16 M
|
$29,000.00
|
$667,000.00
|
-$594,000.00
|
$273,000.00
|
-$4.18 M
|
$2.02 M
|
$3.98 M
|
$9.64 M
|
$37.22 M
|
| Income Before Tax |
-$69.05 M |
-$36.92 M |
-$23.16 M |
-$22.18 M |
-$19.48 M |
-$12.44 M |
-$14.14 M |
-$19.39 M |
-$589,000.00 |
$23.11 M |
| Income Before Tax Ratio
|
-15.25
|
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
-122.96
|
-74.59
|
-1.24
|
56.5
|
| Income Tax Expense |
$0.00 |
-$29,000.00 |
$64,000.00 |
$634,000.00 |
-$454,000.00 |
-$328,000.00 |
-$1.30 M |
-$556,000.00 |
-$73,000.00 |
-$37.22 M |
| Net Income |
-$69.05 M |
-$36.89 M |
-$23.22 M |
-$22.82 M |
-$19.03 M |
-$12.11 M |
-$12.84 M |
-$18.84 M |
-$516,000.00 |
$23.11 M |
| Net Income Ratio |
-15.25 |
-6.7 |
-5.19 |
-27.72 |
0 |
0 |
-111.63 |
-72.45 |
-1.09 |
56.5 |
| EPS |
-1.91 |
-1.08 |
-0.96 |
-1.39 |
-2.43 |
-8.9 |
-28.14 |
-268.06 |
-13.35 |
589.4 |
| EPS Diluted |
-1.91 |
-1.08 |
-0.96 |
-1.39 |
-2.43 |
-8.9 |
-27.34 |
-268.06 |
-13.35 |
-326.2 |
| Weighted Average Shares
Out |
$36.08 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$7.83 M
|
$1.36 M
|
$456,247.00
|
$70,275.00
|
$38,651.00
|
$26,761.00
|
| Weighted Average Shares
Out Diluted |
$36.08 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$7.83 M
|
$1.36 M
|
$469,582.00
|
$70,275.00
|
$38,651.00
|
$42,048.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
